GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with focus on nutraceuticals and pharmaceuticals in Canada. The company develops Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Renochlor, a dietary supplement to support kidney health; and Sucanon, a herbal health supplement to manage blood… Read more
GenixPharmaceucticals Corporation (GENX) - Net Assets
Latest net assets as of April 2025: CA$-1.34 Million CAD
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has net assets worth CA$-1.34 Million CAD as of April 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$41.67K) and total liabilities (CA$1.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-1.34 Million |
| % of Total Assets | -3221.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | -124.36% |
| 10-Year Change | N/A |
| Growth Volatility | 53.03 |
GenixPharmaceucticals Corporation - Net Assets Trend (2015–2024)
This chart illustrates how GenixPharmaceucticals Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GenixPharmaceucticals Corporation (2015–2024)
The table below shows the annual net assets of GenixPharmaceucticals Corporation from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-10-31 | CA$-1.18 Million | -4.03% |
| 2023-10-31 | CA$-1.14 Million | -135.55% |
| 2022-10-31 | CA$3.20 Million | -20.31% |
| 2021-10-31 | CA$4.01 Million | -17.36% |
| 2020-10-31 | CA$4.86 Million | +11627.99% |
| 2019-10-31 | CA$-42.13K | -134.38% |
| 2018-10-31 | CA$122.57K | +1.32% |
| 2017-10-31 | CA$120.97K | -68.53% |
| 2016-10-31 | CA$384.43K | -24.16% |
| 2015-10-31 | CA$506.89K | -- |
Equity Component Analysis
This analysis shows how different components contribute to GenixPharmaceucticals Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 833283100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$11.02 Million | % |
| Total Equity | CA$-1.18 Million | 100.00% |
GenixPharmaceucticals Corporation Competitors by Market Cap
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Greenlit Ventures Inc
PINK:GLVT
|
$452.32K |
|
Sprott Physical Gold and Silver Trust
TO:CEF
|
$452.56K |
|
Tangiamo Touch Technology AB
ST:TANGI
|
$452.63K |
|
BARNES GROUP
BE:BG4
|
$453.29K |
|
EGRNF
PINK:EGRNF
|
$451.82K |
|
James Bay Resources Limited
PINK:JMBRF
|
$451.01K |
|
Community Redevelopment Inc
PINK:CRDV
|
$450.08K |
|
PSI F.PR.U.SYS N
MU:PSAN
|
$449.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GenixPharmaceucticals Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -1,137,361 to -1,183,200, a change of -45,839.
- Net loss of 73,196 reduced equity.
- Other factors increased equity by 27,357.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-73.20K | -6.19% |
| Other Changes | CA$27.36K | +2.31% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares GenixPharmaceucticals Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-10-31 | CA$0.00 | CA$0.02 | x |
| 2018-10-31 | CA$0.00 | CA$0.02 | x |
| 2019-10-31 | CA$0.00 | CA$0.02 | x |
| 2020-10-31 | CA$0.08 | CA$0.02 | x |
| 2021-10-31 | CA$0.07 | CA$0.02 | x |
| 2022-10-31 | CA$0.05 | CA$0.02 | x |
| 2023-10-31 | CA$-0.02 | CA$0.02 | x |
| 2024-10-31 | CA$-0.02 | CA$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GenixPharmaceucticals Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1806.86%
- • Asset Turnover: 0.09x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-32.25%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -107.71% | -83.89% | 1.05x | 1.22x | CA$-596.67K |
| 2016 | -33.57% | -13.96% | 2.04x | 1.18x | CA$-167.49K |
| 2017 | -201.05% | -24.07% | 2.57x | 3.26x | CA$-255.30K |
| 2018 | 109.39% | 31.92% | 1.81x | 1.89x | CA$121.81K |
| 2019 | 0.00% | -119.87% | 3.41x | 0.00x | CA$-160.49K |
| 2020 | -14.80% | 0.00% | 0.00x | 1.10x | CA$-1.20 Million |
| 2021 | -41.17% | 0.00% | 0.00x | 1.19x | CA$-2.05 Million |
| 2022 | -33.57% | 0.00% | 0.00x | 1.33x | CA$-1.39 Million |
| 2023 | 0.00% | -35600.34% | 0.06x | 0.00x | CA$-4.28 Million |
| 2024 | 0.00% | -1806.86% | 0.09x | 0.00x | CA$45.12K |
Industry Comparison
This section compares GenixPharmaceucticals Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $156,649,455
- Average return on equity (ROE) among peers: -332.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GenixPharmaceucticals Corporation (GENX) | CA$-1.34 Million | -107.71% | N/A | $451.93K |
| Amotiv Limited (AOV) | $1.03 Billion | 2.34% | 0.02x | $227.52 Million |
| Cannabist Company Holdings Inc (CBST) | $-986.97K | 0.00% | 0.00x | $11.81 Million |
| DRI Healthcare Trust (DHT-U) | $372.34 Million | 3.11% | 0.70x | $450.44 Million |
| Simply Solventless Concentrates Ltd. (HASH) | $1.78 Million | -130.46% | 0.98x | $2.81 Million |
| The Hempshire Group Corp. (HMPG) | $-835.46K | 0.00% | 0.00x | $515.15K |
| LSL Pharma Group Inc. (LSL) | $7.48 Million | 1.18% | 2.18x | $24.09 Million |
| Good Shroom Co Inc (MUSH) | $242.01K | -170.37% | 3.22x | $2.78 Million |
| Navasota Resources Inc. (NAV) | $3.47K | -2698.16% | 31.31x | $132.92K |
| Verano Holdings Corp Ordinary Shares - Class A (Sub Voting) (VRNO) | $-216.50K | 0.00% | 0.00x | $303.72 Million |